E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Moderate to Severe Psoriasis |
|
E.1.1.1 | Medical condition in easily understood language |
Moderate to Severe Psoriasis |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10037153 |
E.1.2 | Term | Psoriasis |
E.1.2 | System Organ Class | 10040785 - Skin and subcutaneous tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To compare the proportion of subjects with moderate to severe psoriasis experiencing a 75% improvement as measured by reduction in psoriasis area and severity index (PASI-75) score after 12 weeks of treatment between doses of BMS-986165 and placebo.
- To assess the safety and tolerability of multiple oral doses of BMS-986165 in subjects with moderate to severe psoriasis |
|
E.2.2 | Secondary objectives of the trial |
To assess that the proportion of subjects (sbj) experiencing a 75% reduction in psoriasis area and severity index (PASI) score in the most efficacious treatment group/To compare the proportions of subjects experiencing a 75% reduction in PASI score between treatment groups/To assess a positive trend btw treatment groups of BMS-986165 and proportion of sbj experiencing a 75% reduction in PASI score aftr 12 wks of treatment/To assess clinical efficacy of BMS-986165 as measured by improvement in skin disease area and severity indices PASI50/75/90/100 over time in sbj with moderate to severe psoriasis/To assess a significantly higher proportion of sbj achieving a static physician’s global assessment (sPGA) score of 0=cleared or 1=minimal after 12 wks of treatment with BMS-986165 than after 12 wks of treatment with placebo/To assess improvement by BMS-986165 in quality of life assessments (DLQI)/To assess the trough concentrations of BMS-986165 in sbj with moderate to severe psoriasis |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male and female, ages 18 to 70 years
- Diagnosis of plaque psoriasis for less or equal to 6 months
- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test, must not be pregnant, lactating, breastfeeding or planning pregnancy.
- Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment plus 5 half-lives of the study drug plus 90 days. |
|
E.4 | Principal exclusion criteria |
- Diagnosis of non-plaque psoriasis
- History or evidence of active infection and/or febrile illness
- Any significant acute or chronic medical illness
- Blood transfusion within 4 weeks of study drug administration
- Inability to tolerate oral medication
- Positive hepatitis-B (HBV) surface antigen
- Positive hepatitis-C (HCV) antibody
- Any history or risk for tuberculosis (TB)
- Any major illness/condition or evidence of an unstable clinical condition
- Chest X-ray findings suspicious of infection at screening
- Has received ustekinumab, secukinumab or ixikizumab within 6 months of first administration of study medication
- Has received anti-TNF inhibitor(s) within 2 months of first administration of study medication
- Has received Rituximab within 6 months of first administration of study medication
- Topical medications/treatments for psoriasis within 2 weeks of the first administration of any study medication
- any systemic medications/treatments for psoriasis within 4 weeks of the first administration of any study medication |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1/ Proportion of subjects reaching a 75% reduction in psoriasis activity and severity index (PASI-75)
2/ Safety and tolerability |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1/ Day 1 to Day 85
2/ Day 1 to 115 |
|
E.5.2 | Secondary end point(s) |
1/ The proportion of subjects reaching a 50% (PASI-50), 75% (PASI-75), 90% (PASI-90) and 100% (PASI-100) reduction in psoriasis activity and severity index
2/ The proportion of subjects reaching "0" and "1" on the static Physician Global Assessment score (sPGA)
3/ Dermatology Life Quality Index score
4/ Pharmacokinetics |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1/ to 4/ : Day 1 to Day 85 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 6 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
Germany |
Japan |
Latvia |
Mexico |
Poland |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 5 |